Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04224493
Title Study in Subjects With Relapsed/Refractory Follicular Lymphoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Epizyme, Inc.

follicular lymphoma


Lenalidomide + Rituximab + Tazemetostat

Lenalidomide + Rituximab

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL

No variant requirements are available.